Trial Profile

A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 19 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 3632 (Primary) ; Antineoplastics; Posaconazole
Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes
Focus Adverse reactions; First in man
Acronyms MOMENTUM
Sponsors AstraZeneca

29 Jan 2026 Status changed from not yet recruiting to recruiting.
28 Nov 2025 Planned End Date changed from 18 Jun 2029 to 15 Feb 2029.
28 Nov 2025 Planned primary completion date changed from 18 Jun 2029 to 15 Feb 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com